Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Real-world Tactics to Address Health Inequities in Multiple Myeloma Care

Premiere Date: Monday, October 17, 2022

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Dietetic Registration (CDR)
7. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Friday, October 17, 2025

Faculty

Joseph Mikhael, MD, MEd, FRCPC, FACP (Moderator) Professor, Applied Cancer Research and Drug Discovery Division Translational Genomics Research Institute (TGen) Phoenix, AZ Chief Medical Officer, International Myeloma Foundation (IMF) Studio City, CA

Saad Z. Usmani, MD, MBA, FACP  Chief of Myeloma Service Chief, Myeloma Service Memorial Sloan Kettering Cancer Center (MSK) Member, Memorial Sloan Kettering Cancer Center Attending Physician, Myeloma, Cellular Therapy and Adult BMT New York, NY

Statement of Need

Multiple myeloma has twice the incidence and death rate in Black people, compared with White people. Yet, Black people are half as likely to undergo a stem cell transplantation despite having similar, if not better, survival rates compared to White people, when given standard of care treatment. Chasms in early diagnosis, treatment options and access, survival rate, and more, remain for racial and ethnic underserved populations. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncology treatment for multiple myeloma, thus resulting in delayed diagnosis and suboptimal clinical management, prognosis, and survival rate.

In this CME Outfitters BriefCase, faculty experts will guide learners through a patient case scenario reflecting the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with multiple myeloma. This program will provide actionable strategies, empowering attendees to recognize factors and implement changes in practice to improve multiple myeloma treatment.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Identify the impact of health inequities on patients with multiple myeloma and develop individual treatment strategies for optimal outcomes.

Financial Support

Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.

Target Audience

Physicians, PAs, nurse practitioners, nurses/nurse navigators, pharmacists, and dieticians specializing in hematology, pathology, radiology, or primary care.

Credit Information

ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning formats: Enduring material

Royal College MOC
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Mikhael reports the following financial relationships:

Consultant: Amgen Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Karyopharm; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Usmani reports the following financial relationships:

Advisory Board: AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; EdoPharma; Genentech, Inc.; Gilead Sciences, Inc.; GSK; Janssen Pharmaceuticals, Inc.; Oncopeptides, Inc.; Sanofi; Seattle Genetics, Inc.; Secura Bio; SkylineDx USA, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teneobio, Inc.

Research Support: Amgen Inc.; Array BioPharma Inc.; Bristol Myers Squibb Company; Celgene Corporation; GSK; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pharmacyclics, Inc.; Sanofi; Seattle Genetics, Inc.; SkylineDx USA, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: Amgen Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; and Sanofi

The following peer reviewer and CME Outfitters staff have no financial relationships:

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)

Meghann Taft-Lockard (planning committee)

David Modrak, PhD (planning committee)

Sandra Caballero, PharmD (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).